Key Highlights
- Mosaic Biosciences welcomes Dr. Malavi Madireddi and Dr. Scott Glaser as Senior Vice Presidents in Drug and Biologics Discovery, respectively.
- Both leaders bring over 25 years of experience in biopharma, contributing to Mosaic’s growth in therapeutic discovery services.
- Their appointments underscore Mosaic’s commitment to innovative protein therapeutics discovery and collaborative research excellence.
Source: Business Wire
Notable Quotes
- “Malavi’s impressive knowledge…and Scott’s strategic expertise…significantly increases the already high value we offer current and prospective partners.” – Eric Furfine, co-CEO & CSO at Mosaic Biosciences
- “I am excited to leverage my drug discovery and clinical development expertise to further position Mosaic Biosciences as the partner of choice.” – Malavi Madireddi, Senior Vice President, Drug Discovery at Mosaic Biosciences
- “Mosaic Biosciences has a strong history of technical innovations and partner support that makes it a leader in the discovery of successful next-generation protein therapeutics.” – Scott Glaser, Senior Vice President, Biologics Discovery at Mosaic Biosciences
SoHC's Take
Mosaic Biosciences’ strategic leadership enhancements with Drs. Madireddi and Glaser mark a pivotal moment in the company’s evolution. Their extensive expertise not only strengthens Mosaic’s position as a leader in drug discovery but also highlights the organization’s adaptability and forward-thinking approach in a rapidly changing biopharmaceutical landscape. These appointments come at a crucial time when the industry seeks more collaborative and innovative pathways to therapeutic discovery. Mosaic’s comprehensive platform and the addition of two seasoned leaders underscore its commitment to advancing health through groundbreaking research and development. This move demonstrates Mosaic’s readiness to meet the growing demand for its services, offering promising prospects for its partners and the wider biopharmaceutical sector.
